Fused Or Hybrid Cell, Per Se Patents (Class 435/346)
-
Patent number: 6300129Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: GrantFiled: December 2, 1996Date of Patent: October 9, 2001Assignee: GenPharm InternationalInventors: Nils Lonberg, Robert M. Kay
-
Patent number: 6297052Abstract: The present invention provides methods of proliferating B cells as a means of obtaining large numbers of B cells. The present invention further provides methods of differentiating a proliferating B cell population to antibody producing cells.Type: GrantFiled: April 24, 1997Date of Patent: October 2, 2001Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Marilyn Kehry, Brian Castle
-
Publication number: 20010021526Abstract: Cybrid cell lines which have utility as model systems for the study of disorders that are associated with mitochondrial defects are described. The cybrids are constructed by treating immortal cell lines with an agent that irreversibly disables mitochondrial electron transport, and then transfecting the cells with mitochondria isolated from diseased tissue samples. Preferably, the immortal cell lines used are of an undifferentiated type that can be induced to differentiate, which results in the cybrids also being able to be induced to differentiate. One such cybrid was constructed using neuroblastoma cells and mitochondria from a patient suffering from Alzheimer's Disease. Methods for using such cybrids for screening drugs and therapies for utility in treating such disorders are also provided. In addition, cybrid animals, methods of producing them, and methods of using them in drug and therapy screening are also provided.Type: ApplicationFiled: April 2, 2001Publication date: September 13, 2001Inventors: Robert E. Davis, Scott W. Miller
-
Patent number: 6284475Abstract: The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The methods of the invention are premised on the inhibition of binding of an anticoagulant protein, annexin, preferably annexin-V, to phospholipids by antiphospholipid (aPL) antibodies in a patient blood sample.Type: GrantFiled: July 10, 1998Date of Patent: September 4, 2001Assignee: Mount Sinai School of Medicine of the City of New YorkInventor: Jacob H. Rand
-
Patent number: 6277964Abstract: The present invention provides monoclonal antibodies suitable for monitoring polycyclic aromatic hydrocarbons (PAHs) by an immunoasay, hybridoma cell lines producing said antibodies, and an immunoassay for analyzing PAHs in a sample using said monoclonal antibodies. In addition, the present invention provides PAH conjugates useful as an immunogen in preparing said antibodies and as a standard substance in a competitive assay.Type: GrantFiled: March 11, 1999Date of Patent: August 21, 2001Assignee: Osaka Gas Company LimitedInventors: Nobuhiko Yamashita, Kazunobu Miura, Naoya Ichimura, Chiwa Kataoka, Junko Sakaki, Yutaka Ohtani, Hirohisa Kitagawa
-
Patent number: 6274347Abstract: A shed form of leukocyte adhesion molecule-1 (LAM-1, L-selectin) is present in high levels in human plasma. Quantitative methods of detecting shed LAM-1 (sLAM-1) by Western blot and ELISA analysis are disclosed. Also disclosed are methods for the specific detection of cell-surface bound LAM-1 in the presence of shed LAM-1 and for immunotherapy using monoclonal antibodies reactive with cell-surface bound LAM-1 but not reactive with shed LAM-1. In addition a method of producing an antibody that is reactive with cell-surface bound LAM-1 but not reactive with shed LAM-1 is disclosed.Type: GrantFiled: January 17, 1997Date of Patent: August 14, 2001Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Thomas F. Tedder, Boris Schleiffenbaum, Olivier Spertini
-
Patent number: 6270989Abstract: The invention relates to novel human DNA sequences, targeting constructs, and methods for producing novel genes encoding thrombopoietin, DNase I, and &bgr;-interferon by homologous recombination. The targeting constructs comprise at least: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) a splice-donor site. The targeting constructs, which can undergo homologous recombination with endogenous cellular sequences to generate a novel gene, are introduced into cells to produce homologously recombinant cells. The homologously recombinant cells are then maintained under conditions which will permit transcription of the novel gene and translation of the mRNA produced, resulting in production of either thrombopoietin, DNase I, or &bgr;-interferon.Type: GrantFiled: March 17, 1995Date of Patent: August 7, 2001Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas A. Treco, Michael W. Heartlein, Brian M. Hauge, Richard F Selden
-
Patent number: 6265214Abstract: The present disclosure relates to a new lymphokine molecule, referred to as Monocyte Cytotoxicity Inducing Factor (MCF), and its use as in cancer and other types of therapy. The disclosure further relates to the development of novel Sezary cell hybridomas which secrete MCF and thereby provide a ready source for MCF isolation and purification. Sezary's Syndrome is a leukemic proliferation of OKT4+ lymphocytes. Sezary cells were isolated by differential centrifugation and fused to CEM.8aza.rC, an HGPRTase lacking clone of CEM. The hybrid cells were studied for their ability to produce soluble mediators of human monocyte cytotoxicity. The product of a single clone, FtF3, which bore the surface phenotype of Sezary cells, was characterized. Monocyte cytotoxicity inducing factor was found to be stable at pH 2 for one hour, unlike interferon-gamma, and was found to be more heat stable as well.Type: GrantFiled: December 7, 1990Date of Patent: July 24, 2001Assignee: Board of Regents, The University of Texas SystemInventor: C. Michael Jones
-
Patent number: 6262239Abstract: Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth cysteine rich domain of the p75 TNF receptor or to the region between said fourth cysteine rich domain and the cell membrane.Type: GrantFiled: June 7, 1995Date of Patent: July 17, 2001Assignee: Yeda Research and Development Co., Ltd.Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
-
Patent number: 6258564Abstract: The invention is related to antibodies which specifically react with connective tissue type-human mast cells, a production method of the antibodies, hybridomas which produce the antibodies, a production method of the hybridomas and antigen proteins recognized by the antibodies. After cord blood cells were cultured in the presence of SCF and IL-6, they were further cocultured with primary culture of human skin fibroblasts, and connective tissue type-human mast cells were thus obtained. A rat was immunized using the cells, hybridomas were prepared and selected by an ordinary method, and novel monoclonal antibodies were harvested from the culture supernatant of the selected hybridomas. The monoclonal antibodies specifically reacted with connective tissue type-human mast cells.Type: GrantFiled: July 29, 1999Date of Patent: July 10, 2001Assignee: Medical & Biological Laboratories Co., Ltd.Inventors: Makoto Kawai, Tadashi Okada, Fukiko Atsumi
-
Patent number: 6255107Abstract: The invention is related to antibodies which specifically react with connective tissue type-human mast cells, a production method of the antibodies, hybridomas which produce the antibodies, a production method of the hybridomas and antigen proteins recognized by the antibodies. After cord blood cells were cultured in the presence of SCF and IL-6, they were further cocultured with primary culture of human skin fibroblasts, and connective tissue type-human mast cells were thus obtained. A rat was immunized using the cells, hybridomas were prepared and selected by an ordinary method, and novel monoclonal antibodies were harvested from the culture supernatant of the selected hybridomas. The monoclonal antibodies specifically reacted with connective tissue type-human mast cells.Type: GrantFiled: January 13, 1999Date of Patent: July 3, 2001Assignee: Medical & Biological Laboratories Co., Ltd.Inventors: Makoto Kawai, Tadashi Okada, Fukiko Atsumi
-
Patent number: 6251670Abstract: An object of the present invention is to provide a method of enabling perfusion culture efficiently and simply by agglutinating cells with Lectin, which is a naturally-occurring agglutinin, thereby separating the cells and the culture medium. According to the method of the present invention, lectin is added to a culture medium to quickly agglutinate and precipitate the cells, thereby separating the culture medium and the cells. Hence, it is easy to remove old culture medium and replenish with fresh culture medium. Accordingly, if the method of the present invention is used, the perfusion culture is performed automatically and on an industrial scale.Type: GrantFiled: June 28, 1999Date of Patent: June 26, 2001Assignee: President of Kanazawa UniversityInventors: Tanihiro Yoshimoto, Hiroyuki Takamatsu
-
Patent number: 6232446Abstract: Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-terminal cysteine loop of the p75 TNF receptor, which loop consists of the amino acid sequence Cys-185 to Thr-201 of SEQ ID NO:3.Type: GrantFiled: June 7, 1995Date of Patent: May 15, 2001Assignee: Yeda Research and Development Co. Ltd.Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
-
Patent number: 6228618Abstract: Methods for enhancing the production of tissue plasminogen activator (tPA) in cell culture are disclosed. The methods involve culturing tPA-producing cells in growth media supplemented with an alkanoic acid or salt thereof at a concentration which enhances tPA production. The most preferred methods utilize butyric acid or sodium butyrate at a concentration of between 0.5 mM and 2.5 mM.Type: GrantFiled: October 22, 1997Date of Patent: May 8, 2001Assignee: Alusuisse Holdings A.G.Inventor: Raymond Paul Field
-
Patent number: 6210670Abstract: This invention provides monoclonal antibodies that bind to both E-selectin and to P-selectin, and inhibit the binding of these proteins to counterreceptors. The invention also provides nucleic acids encoding these antibodies and methods for using the antibodies in the treatment of inflammatory conditions.Type: GrantFiled: March 26, 1996Date of Patent: April 3, 2001Assignee: Protein Design Labs, Inc.Inventor: Ellen L. Berg
-
Patent number: 6207452Abstract: A domain of Bcl-2 that suppresses apoptosis by allowing cell survival permits cell proliferation when mutated. The wild type domain includes amino acid residues 51 to 97 (SEQ ID NO:13) of Bcl-2. Peptides including the domain and nucleotides encoding the domain are useful in molecular screening of human tumors for the presence of mutations that allow proliferation of cells that were otherwise marked for apoptosis. The peptides are also useful to screen for proteins that play a role in the modulation of cellular proliferation.Type: GrantFiled: March 23, 1999Date of Patent: March 27, 2001Assignee: St. Louis University Health Sciences CenterInventor: Chinnadurai Govindaswamy
-
Patent number: 6207418Abstract: The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.Type: GrantFiled: June 29, 1999Date of Patent: March 27, 2001Assignees: Abgenix, Inc., Japan Tobacco Inc.Inventors: Nobuaki Hori, Claude Geoffrey Davis, Krisztina M. Zsebo, Aya Jakobovits
-
Patent number: 6207156Abstract: The present invention relates to methods and products for immunotherapy resulting in the stimulation of T-cell proliferation. The products of the invention are peptides that bind to CTLA-4 and co-stimulate the proliferation of T-cells by inhibiting the binding of B7 to CTLA-4. Pharmaceutical compositions including such peptides are also provided. The invention further provides in vitro and in vivo therapeutic methods employing the peptides of the invention.Type: GrantFiled: March 18, 1998Date of Patent: March 27, 2001Assignee: Brigham and Women's Hospital, Inc.Inventors: Vijay K. Kuchroo, Edward A. Greenfield
-
Patent number: 6197582Abstract: The present invention provides a trioma cell which does not produce any antibody obtained by fusing a hetermomyeloma cell which does not produce any antibody with a human lymphoid cell, wherein the heteromyeloma cell is designated B6B11. The invention also provides a tetroma cell capable of producing a monoclonal antibody having specific binding affinity for an antigen obtained by fusing a trioma cell which does not produce any antibody with a human lymphoid cell capable of producing antibody having specific binding affinity for the antigen. The invention also provides methods for generating trioma cells and tetroma cells, and the cells generated by the methods.Type: GrantFiled: March 18, 1998Date of Patent: March 6, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventor: Ilya Trakht
-
Patent number: 6184359Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: November 9, 1998Date of Patent: February 6, 2001Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 6183971Abstract: Disclosed are an antibody which have a binding activity to human betacellulin protein or a mutein thereof with specificity; especially a monoclonal antibody which does not have cross reactitivity with human epidermal growth factor (EGF) and human transforming growth factor a (TGF-&agr;), belongs to the immunoglobulin class of IgG, and,specifically binds to human betacellulin protein to neutralize biological activity thereof; a hybridoma for producing the monoclonal antibody; and a method for producing the monoclonal antibody. Said monoclonal antibody neutralizes biological activity of a human BTC protein, and bind to the protein with high sensitivity and specificity, so that they can be used as a therapeutic agent for diseases such as arterial sclerosis and cancers, and also used as a reagent for assaying the human BTC protein or a mutein thereof and as a diagnostic agent for diabetes or complications thereof.Type: GrantFiled: June 11, 1996Date of Patent: February 6, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Reiko Sasada, Tatsuya Watanabe, Yukio Toyoda
-
Patent number: 6174726Abstract: The invention is directed to a method for the preparation of a conditionally immortalized immortalization-helper cell (fuseme), the fusemes generated by said method, hybridoma cells prepared using said fusemes as well as a method for immortalization of mammalian cells using said fuseme cells. Further, the invention relates to the generation of T cells directed agaist tumor cells using a fuseme cell.Type: GrantFiled: April 1, 1999Date of Patent: January 16, 2001Assignee: GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbHInventors: Martin Staege, Georg Bornkamm, Bettina Kempkes
-
Patent number: 6174723Abstract: A method for preparing a cocaine-protein conjugate easily by using a cocaine derivative having a methoxy carbonyl group and benzoyl group. This conjugate is useful for the detection of cocaine or cocaine derivatives. A monoclonal antibody, a monoclonal antibody producing cell line, and a method for producing the monoclonal antibody producing cell line by using the above cocaine-protein conjugate as an immunogen is also described.Type: GrantFiled: December 2, 1997Date of Patent: January 16, 2001Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Keiko Yugawa, Nobuyuki Sigetoh, Jinsei Miyazaki, Tadayasu Mitsumata
-
Patent number: 6172199Abstract: The present invention provides a polynucleotide (ubcp) which identifies and encodes a novel ubiquitin-conjugating enzyme (UBCP). The invention provides for genetically engineered expression vectors and host cells comprising the nuclei acid sequence encoding UBCP. The invention also provides for the use of substantially purified UBCP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of UBCP. Additionally, the invention provides for the use of antisense molecules to ubcp in pharmaceutical compositions for treatment of diseases associated with the expression of UBCP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ubcp or anti-UBCP antibodies which specifically bind to UBCP.Type: GrantFiled: May 25, 1999Date of Patent: January 9, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 6171588Abstract: Monoclonal antibodies that recognize the &agr;v &bgr;3 integrin receptor complex, but do not significantly bind to &agr;IIb&bgr;IIIa, inhibit &agr;v&bgr;3 integrin-mediated diseases.Type: GrantFiled: April 9, 1998Date of Patent: January 9, 2001Assignee: G. D. Searle & CompanyInventors: Christopher P. Carron, Debra M. Meyer, George A. Nickols
-
Patent number: 6162902Abstract: The present invention provides reagents and assays for the quantification of hBNP in biological fluid samples such as plasma or serum. Antibodies are provided which are monospecific to epitopes comprising the amino acid sequences 5-13, 1-10 and 15-25 of hBNP. These antibodies, and peptide fragments containing these sequences, can be employed in the assays of the invention, which may be carried out in a sandwich format or a competition format.Type: GrantFiled: October 1, 1997Date of Patent: December 19, 2000Assignee: Scios Inc.Inventors: Ronald P. Mischak, Garrett A. Lim, Jan Marian Scardina
-
Patent number: 6136309Abstract: Antibodies directed against the ligand-binding component of the interferon (IFN)-.alpha./.beta. receptor (IFN.alpha./.beta.R, IFNAR2) are provided. The antibodies are capable of selectively modulating the activity of IFN-.alpha. as compared to IFN-.beta.. By virtue of their selectivity, the antibodies are useful in clinical and analytical applications.Type: GrantFiled: October 29, 1998Date of Patent: October 24, 2000Assignee: Yeda Research and Development Co. Ltd.Inventors: Daniela Novick, Menachem Rubinstein
-
Patent number: 6136599Abstract: Human/human hybrid cells were made via fusion of human embryonic kidney cells (293S) and modified Burkitt's lymphoma cells (2B8). The fusion cells are useful as host cells for the recombinant expression of mammalian genes. The advantages of using these hybrid clones of human kidney- and B-cells, called HKBs, for mammalian gene expression, include (i) the cells are negative for immunoglobulin expression, (ii) the cells grow easily in plasma protein-free medium (with or without the addition of recombinant insulin) as suspension cultures in a shake flask or in a fermenter (iii) the cells are very susceptible for transfection of DNA, and (iv) the cells secrete high levels of heterologous recombinant proteins, such as recombinant monoclonal antibodies, soluble ICAM-1, rIL-4, and rFVIII.Type: GrantFiled: December 10, 1998Date of Patent: October 24, 2000Assignee: Bayer CorporationInventor: Myung-Sam Cho
-
Patent number: 6130086Abstract: The present invention aims to provide a medium composition for in vitro fertilization, in particular, a composition usable in the culture of ova or early embryos which are fertilized eggs, the preparation or culture of sperm, and the pre-treatment of ova or sperm.The composition comprises, as its essential components, L-phenylalanine, L-tryptophan, L-lysine, L-threonine, L-valine, L-methionine, L-isoleucine, L-leucine, L-proline, glycine, L-alanine, L-tyrosine, L-histidine, L-arginine, L-taurine, L-aspartic acid, L-serine, L-asparagine, L-glutamic acid, L-glutamine and L-cystine, provided that at least a part of the L-cystine may be replaced by L-cysteine.Type: GrantFiled: March 2, 1998Date of Patent: October 10, 2000Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Teruki Nakazawa, Hiromasa Araki, Yuichiro Kishi, Sanji Shinoda, Moriyuki Yamada, Kazutomo Ohashi
-
Patent number: 6117652Abstract: Methods for enhancing the production of tissue plasminogen activator (tPA) in cell culture are disclosed. The methods involve culturing tPA-producing cells in growth media supplemented with an alkanoic acid or salt thereof at a concentration which enhances tPA production. The most preferred methods utilize butyric acid or sodium butyrate at a concentration of between 0.1 mM and 10 mM.Type: GrantFiled: May 14, 1997Date of Patent: September 12, 2000Assignee: Alusuisse Holdings, A.G.Inventor: Raymond Paul Field
-
Patent number: 6113898Abstract: The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: GrantFiled: June 7, 1995Date of Patent: September 5, 2000Assignee: IDEC Pharmaceuticals CorporationInventors: Darrell R. Anderson, Peter Brams, Nabil Hanna, William S. Shestowsky, Cheryl Heard
-
Patent number: 6090621Abstract: Novel polypeptides called signaling inositol polyphosphate 5-phosphatases are described called SIP-130, SIP-125, and SIP-N. SIP-130 is capable of binding to aPTB domain of SH2 and collagen containing protein (SHC). Also provided are polynucleotide sequences encoding the novel polypeptides, as well as vectors and host cells containing the polynucleotides. Further provided are modulators including agonists and antagonists of the novel polypeptides for use as therapeutics, including antibodies, polypeptides, small molecules, and polynucleotides and methods of using the therapeutics in treatment of diseases associated with abnormal cell growth. Methods of making the polypeptides, polynucleotides, vectors, host cells, antibodies, and small molecules are also provided. Gene delivery vehicles including SIP and SIP activity-modulating polynucleotides are described.Type: GrantFiled: November 19, 1998Date of Patent: July 18, 2000Assignee: Chiron CorporationInventors: W. Michael Kavanaugh, David Pot, Lewis T. Williams
-
Patent number: 6063620Abstract: The present invention relates to a novel hybridoma cell line which secretes monoclonal antibodies capable of binding to the AT.sub.1 subtype of the Angiotensin II receptor. It also relates to monoclonal antibodies secreted by the hybridoma, which antibodies may be used in diagnostic test kits as well as having therapeutic applications.Type: GrantFiled: March 27, 1996Date of Patent: May 16, 2000Assignee: Queen Mary & Westfield CollegeInventors: Gavin Paul Vinson, Stewart Barker
-
Patent number: 6063375Abstract: An isolated cell having the characteristics of the cell line designated FO-1 #12 is provided. The cell FO-1 #12 is characterized as being .beta..sub.2 -microglobulin-deficient, neomycin-resistant and HAT-sensitive. A cell hybrid formed by the fusion of an FO-1 #12 cell or other cell described herein and a mammalian cell is provided. The patient-derived cell can be a tumor cell or other cell, such as a white blood cell. The patient-derived tumor cell can be a melanoma cell, a prostatic carcinoma cell, a colon carcinoma cell, a lung carcinoma cell, a breast carcinoma cell, a pancreatic carcinoma cell, or others. A method of treating AIDS in a patient, comprising administering to the patient a cell hybrid provided herein, wherein the patient-derived white blood cell is derived from the patient being treated, is provided.Type: GrantFiled: September 10, 1996Date of Patent: May 16, 2000Assignee: Medical University of South CarolinaInventors: Sebastiano Gattoni-Celli, Danforth A. Newton, III, Edward F. McClay
-
Patent number: 6056957Abstract: A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy and light chain variable regions of the monoclonal antibody and CDRs therefrom; humanized monoclonal antibodies; and pharmaceutical compositions comprising the monoclonal antibody or anti-idiotypic antibodies directed against it, humanized monoclonal antibodies, binding fragments, binding compositions or single-chain binding proteins derived from the antibody and a physiologically acceptable carrier.Type: GrantFiled: August 4, 1994Date of Patent: May 2, 2000Assignee: Schering CorporationInventors: Chuan-Chu Chou, Nicholas J. Murgolo, John S. Abrams, Chung-Her Jenh, Mary E. Petro, Jon E. Silver, Stephen Tindall, William T. Windsor, Paul J. Zavodny
-
Patent number: 6051229Abstract: CLNH5 and CLNH11 specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.Type: GrantFiled: May 18, 1995Date of Patent: April 18, 2000Assignee: The Regents of the University of CaliforniaInventors: Harold H. Handley, Mark C. Glassy, Hideaki Hagiwara, Yoshihide Hagiwara
-
Patent number: 6051693Abstract: CLNH11-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.Type: GrantFiled: June 7, 1995Date of Patent: April 18, 2000Assignee: The Regents of the University of CaliforniaInventors: Harold H. Handley, Mark C. Glassy, Hideaki Hagiwara, Yoshihide Hagiwara
-
Patent number: 6033667Abstract: The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.Type: GrantFiled: November 5, 1997Date of Patent: March 7, 2000Assignee: Cytel CorporationInventors: Robert W. Chesnut, Margaret J. Polley, James C. Paulson, S. Tarran Jones, Jose W. Saldanha, Mary M. Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn
-
Patent number: 6030616Abstract: Molecules which are capable of specifically binding to a hepatitis B escape mutant antigenic determinant include monoclonal antibodies secreted by the cell line SMH HBs 145/G/R/I (ECACC 92122312). SMH HBs 145/R/I (ECACC 93052626). SMH HBs 145/G/II (ECACC 93033109) or SMH HBs 145/R/II (ECACC 93033110) and other specific binding molecules cross-competitive with them. Antibodies secreted by the cell lines SM HBs 145/G/R/I and SMH HBs 145/G/R/II bind variant (escape mutant) HBsAG and wild type HBsAG. Antibodies secreted by the cell lines SMH HBs 145/R/I and SMH HBs 145/R/II bind variant but not wild type.Type: GrantFiled: August 28, 1995Date of Patent: February 29, 2000Assignee: Imperial College of Science, Technology & MedicineInventors: Jennifer Anne Waters, William Frederick Carman, Howard Christopher Thomas
-
Patent number: 6020478Abstract: The present invention provides a human tumor-associated antigen (PRAT) and polynucleotides which identify and encode PRAT. In addition, the invention provides expression vectors and host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with the expression of PRAT.Type: GrantFiled: February 28, 1997Date of Patent: February 1, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli, Hong Zhang
-
Patent number: 6013484Abstract: Described is a new variety of retrovirus designated HIV-3, samples of which are deposited in the European Collection of Animal Cell Cultures (ECACC) under V88060301. Further described are antigens obtained from the virus, particularly proteins p12, p16, p25 and glycoproteins gp41 and gp120 to be used in the diagnosis of ARC or AIDS caused by HIV-3. Immunogenic compositions to be used as vaccines contain an envelope glycoprotein of HIV-3 such as gp41 or gp120.Type: GrantFiled: July 25, 1997Date of Patent: January 11, 2000Assignee: Innogenetics N.V.Inventors: Robert De Leys, Bart Vanderborght, Eric Saman, Hugo Van Heuverswyn
-
Patent number: 6007807Abstract: A hybrid fusion cell comprising:a) a malignant B cell which expresses an idiotypic antibody; andb) a hybridoma which expresses an antibody which is capable of being internalized on a professional antigen presenting cell.Type: GrantFiled: August 25, 1997Date of Patent: December 28, 1999Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Ralf Mocikat, Horst Lindhofer, Stefan Thierfelder
-
Patent number: 6004553Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.Type: GrantFiled: February 9, 1998Date of Patent: December 21, 1999Assignees: Genentech, Inc., Tularik, Inc.Inventors: David V. Goeddel, Mike Rothe
-
Patent number: 5985278Abstract: The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:reacting only with the .alpha.V-chain of human .alpha.V-integrins,blocking the attachment to the integrin substrate of the .alpha.V-integrin bearing cell,triggering reversal of established cell matrix interaction caused by .alpha.V-integrins,blocking tumor development, andshowing no cytotoxic activity.Type: GrantFiled: December 19, 1995Date of Patent: November 16, 1999Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Francesc Mitjans, Jaume Piulats, Elisabet Rosell, Jaume Adan, Simon Goodman, Diane Hahn
-
Patent number: 5976876Abstract: This invention provides an antibody which specifically binds to hLH.beta.cf without cross-reacting with hLH, hLH.beta. or hCG.beta.cf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No.12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLH.beta.cf or hLH.beta.cf-related molecule in a sample.Type: GrantFiled: December 11, 1996Date of Patent: November 2, 1999Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Steven Birken, John O'Connor, Galina Kovalevskaya
-
Patent number: 5972623Abstract: The invention includes a method of determining the level of Type I collagen fragments in a biological fluid using an antibody which is immunospecific for an epitope contained in one of the following sequences:(1) Ala-Hyp-Gly-Asp-Arg-Gly-Glu-Hyp-Gly-Pro-Hyp-Gly-Pro-Ala, or(2) Gly-Asn-Ser-Gly-Glu-Hyp-Gly-Ala-Hyp.under conditions effective to allow determination of the level of collagen fragments in the sample which contain the epitope. The method is useful for assessing the level of bone collagen degradation, particularly in humans. Also disclosed are antibodies and kits which can be used in the method.Type: GrantFiled: July 31, 1998Date of Patent: October 26, 1999Assignee: Metra Biosystems, Inc.Inventors: Stephen M. Krane, Michael H. Byrne, Hsin-Shan Julia Ju, Scott D. Leigh
-
Patent number: 5961974Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.Type: GrantFiled: May 24, 1994Date of Patent: October 5, 1999Assignee: Immunex CorporationInventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
-
Patent number: 5962291Abstract: The present invention relates to catalytic antibodies and a method for producing the same wherein a host is immunized using an "antigen chelate" or more specifically a stable compound capable of chelating metal ions. The immune response mounted in response to the antigen chelate produces antibodies that are capable of binding both a substrate and a metal ion, thus achieving a metal cofactor assisted reaction.Type: GrantFiled: October 10, 1997Date of Patent: October 5, 1999Assignee: The Regents of the University of ColoradoInventors: Darla A. Graff, Marvin H. Caruthers, Jeffrey W. Jacobs
-
Patent number: 5948893Abstract: The invention pertains to a murine hybridoma cell (ATCC HB 11944) that secretes a monoclonal antibody (PV-1) that binds to the CD 28 receptor. The antibody selectively stimulates the production of T-Cell populations to proliferate and expand in the absence of exogenous growth factors and accessory cells.Type: GrantFiled: January 17, 1996Date of Patent: September 7, 1999Assignee: The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Nancy Craighead
-
Patent number: 5948647Abstract: Novel compositions are provided that are derived from antigen-binding sites of immunoglobulins having affinity for cancer antigens. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human tumor cell displaying a MDR phenotype. A number of synthetic molecules are provided that include CDR and FR regions derived from same or different immunoglobulin moieties. Also provided are single chain polypeptides wherein V.sub.H and V.sub.L domains are attached by a single polypeptide linker. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for various cancers.Type: GrantFiled: June 7, 1995Date of Patent: September 7, 1999Assignee: Chiron CorporationInventor: David B. Ring